Semaglutide is part of a class of drugs called GLP-1 receptor agonists. GLP-1 is a hormone that your body naturally produces after eating to help regulate important processes like digestion and satiety. When you take Semaglutide, it binds to and activates GLP-1 receptors in the brain and other organs. This can have several metabolic benefits:

• Reduced appetite: By activating GLP-1 receptors in the brain's hunger and satiety centers, Semaglutide may leave you feeling fuller for longer after eating. This can help you to eat less.
• Delayed gastric emptying: GLP-1 slow down digestive processes like emptying of the stomach. This causes decreased food consumption.
• Increased feeling of fullness: The activation of GLP-1 receptors may make stomach stretch signals stronger. This enhances that physically full feeling after eating smaller portions.
• Better blood sugar control: Semaglutide also affects the pancreas, stimulating insulin secretion and inhibiting glucagon release. This helps balance blood sugar levels and prevent spikes/crashes that can trigger hunger.
• Improved cholesterol and triglyceride levels: Tirzepatide influences liver and fat metabolism in a way that favors healthier lipid profiles.

Over time the appetite suppression and metabolic effects of Semaglutide can help people lose weight by reducing calorie intake and increasing calorie burn. Studies show it leads to weight loss of about 15% of body weight on average when combined with a healthy lifestyle. The most common side effects include nausea, vomiting, constipation, indigestion, and stomach (abdominal) pain. These are not all the possible side effects of Semaglutide. Talk to your healthcare provider about any side effects.

• If you take birth control pills talk to your healthcare provider. Birth control pills may not work as well while using Semaglutide. Your healthcare provider may recommend another type of birth control for 4 weeks after you start Semaglutide or Tirzepatide and for 4 weeks after each increase in your dose.
• There is an increased risk of miscarriage associated with the use of GLP-1 agonists during pregnancy.